H.C. Wainwright Maintains Buy Rating on GH Research (GHRS)

GH Research PLC (NASDAQ:GHRS) is one of the 10 Stocks That Have the Potential to Rise 1000%.

On May 19, 2026, H.C. Wainwright lowered the firm’s price target on GH Research PLC (NASDAQ:GHRS) to $65 from $70 and maintained a Buy rating on the shares. H.C. Wainwright cited share count dilution from the company’s April offering for the target cut.

On May 15, 2026, Cantor Fitzgerald raised the firm’s price target on GH Research PLC (NASDAQ:GHRS) to $35 from $25 and maintained an Overweight rating on the shares. Cantor Fitzgerald said GH Research operates in a large and expanding psychedelic therapy market with significant unmet mental health needs. The firm said long-term peak sales across related treatments could reach roughly $50B, supporting a constructive demand backdrop despite uncertainty around competitive dynamics.

H.C. Wainwright Maintains Buy Rating on GH Research (GHRS)

A day earlier, GH Research PLC (NASDAQ:GHRS) reported Q1 EPS of (31c), compared to the consensus estimate of (26c). CEO Velichka Valcheva said the quarter marked progress toward the company’s global GH001 Phase 3 pivotal program.

GH Research PLC (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company developing treatments for depression in the United States.

While we acknowledge the risk and potential of GHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GHRS and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1